As of Oct 17
| +2.15 / +1.57%|
The 26 analysts offering 12-month price forecasts for Celgene have a median target of 156.00, with a high estimate of 175.00 and a low estimate of 116.00. The median estimate represents a +12.34% increase from the last price of 138.86.
The current consensus among 30 polled investment analysts is to Buy stock in Celgene. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.